Spero Therapeutics, Inc. (NASDAQ:SPRO) saw recent insider activity as Esther Rajavelu, serving as the company's CEO, CFO, and Chief Business Officer, executed a sale of 25,240 shares of common stock on May 4, 2026. The transaction took place at $2.51 per share, totaling roughly $63,352. Notably, this was an automated "sell to cover" sale designed to manage tax withholding requirements related to the vesting of restricted stock units (RSUs), rather than a discretionary market trade by Ms. Rajavelu.
Despite this transaction, Ms. Rajavelu remains heavily invested in the company, directly holding 986,851 shares. This occurs against a backdrop of significant stock performance; over the last year, SPRO has seen returns of 338%. As of the reporting period, the company maintains a market capitalization of $146 million with the stock trading at $2.53.
Financial Performance and Strategic Drivers
The recent insider activity follows a period of robust financial results for Spero Therapeutics. In its fourth-quarter report, the company outperformed analyst expectations across several key metrics. Most notably, adjusted earnings per share reached $0.53, which was a significant beat compared to the consensus expectation of -$0.20.
Revenue performance also showed substantial momentum. The company reported quarterly revenue of $41.3 million, which exceeded the forecasted $26 million. This represents a 175% year-over-year increase from the $15.0 million reported in the fourth quarter of 2024. This surge in revenue was primarily driven by increased collaboration revenue stemming from agreements with GSK and Pfizer.
The company's bottom line has also seen a dramatic shift. For the quarter, Spero reported a net income of $31.5 million, a major turnaround from the net loss of $20.9 million recorded during the same period in the previous year. On an annual basis for 2025, Spero posted a net income of $8.6 million ($0.15 per diluted share), compared to a net loss of $68.6 million ($1.27 per share) in 2024.
Key Market Insights
Key Points:
- Revenue Growth Drivers: The company's financial health is currently bolstered by strategic collaboration revenue from major entities like Pfizer and GSK, impacting the biotechnology and pharmaceutical partnership sectors.
- Profitability Turnaround: Spero has transitioned from significant annual losses in 2024 to a net income in 2025, reflecting improved unit economics and margin structures within the biotech market.
Risks and Uncertainties:
- Dependency on Collaborations: Much of the recent revenue growth is attributed to agreements with GSK and Pfizer, suggesting that fluctuations in these specific partnerships could impact future revenue stability in the pharmaceutical sector.
- Market Volatility: While the stock has seen 338% returns over the past year, the current market capitalization and price levels remain subject to the volatility inherent in the biotechnology sector.